Long-term clinical outcomes of stereotactic radiotherapy for bilateral vestibular schwannomas in neurofibromatosis type 2 patients
Journal of Neuro-Oncology · 2023-09 · 164 (3) · 587-595
DOI: 10.1007/s11060-023-04430-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuro-Oncology, online erschienen am 13.09.2023. Verfasst von Putipun Puataweepong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic and Therapeutic Radiology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. putipun.pua@mah…. Hauptthemen laut MEDLINE: Neurofibromatosis 2, Neuroma, Acoustic, Radiosurgery. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: The evidence for treating patients with neurofibromatosis 2-related vestibular schwannoma (VS-NF2) using hypofractionated stereotactic radiation therapy (HSRT) is limited. This study aimed to investigate clinical outcomes in patients with VS-NF2 treated with Robotic HSRT. METHODS: We retrospectively analyzed 25 NF2 patients with 48 VSs who were treated using Robotic HSRT at Ramathibodi Hospital from January 2009 to January 2020. RESULTS: Median follow-up was 98 months (range, 24-155 months). Median tumor volume was 2.3 cm3 (range, 0.4-28.3 cm3). Median prescribed dose was 18 Gy (range, 18-25 Gy) in three fractions (range, 3-5). The 5- and 10-year local control rates were 87% and 80%, respectively. The 5- and 10-year hearing preservation rates were 59% and 35%, respectively. Three patients developed new symptoms associated with transient volume expansion after treatment: hydrocephalus in one, facial weakness in one, and ataxia in one. No patient developed worsening of trigeminal nerve function. No histologically confirmed of radiation induced malignancy was reported in the study. CONCLUSIONS: Robotic HSRT demonstrated excellent long-term tumor control with a low non-auditory complication rate in patients with VS-NF2. However, preservation of hearing remains a major concern.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Diagnostic and Therapeutic Radiology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. putipun.pua@mahidol.ac.th.
- Department of Diagnostic and Therapeutic Radiology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
- Department of Surgery, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
- Radiosurgery Unit, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Zitieren
APA
Puataweepong, P., Dhanacha, M., Ruangkanchanasetr, R., Boonyawan, K., Hansasuta, A., Saetia, K., & Yongvithisatid, P. (2023). Long-term clinical outcomes of stereotactic radiotherapy for bilateral vestibular schwannomas in neurofibromatosis type 2 patients. Journal of Neuro-Oncology, 164(3), 587-595. https://doi.org/10.1007/s11060-023-04430-3
Vancouver
Puataweepong P, Dhanacha M, Ruangkanchanasetr R, Boonyawan K, Hansasuta A, Saetia K, et al. Long-term clinical outcomes of stereotactic radiotherapy for bilateral vestibular schwannomas in neurofibromatosis type 2 patients. Journal of Neuro-Oncology. 2023;164(3):587-595. doi:10.1007/s11060-023-04430-3
BibTeX
@article{Puataweepong2023,
author = {Puataweepong, Putipun and Dhanacha, Mantana and Ruangkanchanasetr, Rawee and Boonyawan, Keeratikarn and Hansasuta, Ake and Saetia, Kriangsak and Yongvithisatid, Pornpan},
title = {Long-term clinical outcomes of stereotactic radiotherapy for bilateral vestibular schwannomas in neurofibromatosis type 2 patients},
journal = {Journal of Neuro-Oncology},
year = {2023},
volume = {164},
number = {3},
pages = {587--595},
doi = {10.1007/s11060-023-04430-3}
}
EUVIMED